Omega's epigenomic programming platform is meant to direct the human genome to treat and cure disease by precisely controlling gene expression without altering native nucleic acid sequences, modulating insulated genomic domains to up- or downregulate single or multiple genes simultaneously.

"We believe this is applicable across the board really, certainly in monogenic diseases, but also importantly in complex multigenic diseases," McCauley told ScienceBoard.net at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington.

The company's programmable mRNA therapeutics, which are called "epigenomic controllers" and are engineered to precisely tune genomic activity with high target specificity and durability, are composed of a DNA-binding domain and an epigenetic effector domain delivered as messenger RNA which modulates gene expression.

At ASGCT 2022, Omega unveiled preclinical data showing the potential of its epigenomic controllers to be developed as standalone therapy or in combination with standard of care therapies in non-small cell lung cancer.

Watch the video below to learn more.

Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge,...

Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the...

Gene expression profile could enable rapid ID of antitumor immune cells
National Institutes of Health researchers, led by Dr. Steven Rosenberg, PhD, at the National Cancer Institute, have found unique expression profiles...

Scientists explain non-small cell lung cancer treatment resistance
A research group has shown why certain T cells do not respond to therapy in patients with non-small cell lung cancer who receive a therapy called immune...